Is achieving your daily goal worth it? An Australian gym was raided by police this week after a trainer’s Apple Watch made an emergency call.
Today on the health front, the White House’s policy of expanding access to the abortion pill is being undermined by federal abortion laws.
Welcome to The Hill’s Health Care roundup, where we keep up with the latest information and news about your health. We are Nathaniel Weixel and Joseph Choi. Write here.
Abortion pills are not available in some areas
Efforts by the Biden administration to liberalize access to the abortion pill in many states threaten to put the drug out of reach for many patients.
Many countries with abortion bans also limit the availability of mifepristone, either through restrictions on who can provide and distribute the pill or outright bans.
- According to the Guttmacher Institute, 18 states require an abortionist to be present when the medication is administered.
- Texas prohibits the use of abortion pills from seven weeks of pregnancy, while Indiana prohibits its use at ten weeks.
In most cases, federal laws take precedence over state laws. Under that proposal, states should not ban mifepristone because it is a federally approved drug.
But it’s unclear whether federal laws will take hold in states that have abortion bans, and so far, the government hasn’t tried to test the theory.
Legal experts and advocates said the overlapping of laws in all states will continue until the court intervenes, creating uncertainty for patients and providers.
The federal government could be the one to bring a lawsuit against state restrictions on mifepristone, but that would open the FDA to unnecessary challenges in restricting its authority.
States have the power to regulate health care services, but there is a question of intent, said Rachel Rebouché, dean of the Temple University Beasley School of Law.
“So, in the states banning mifepristone or trying to control it… he asked.
Read more here.
Advocates also look ahead to Roe’s 50th anniversary
Activists and lawmakers on both sides of the abortion issue are marking the 50th anniversary of the Roe v. Wade Sunday in an effort to reinvigorate supporters and renew their goals, a landmark decision was overturned last summer by the Supreme Court.
- Both sides are using the day to remind supporters of what’s still at stake, and highlight how the fight for abortion rights has shifted from the courts to Congress and states.
- The split in Congress means that the government’s action on abortion is unlikely for the next two years. But officials in all states agree that it is exciting news for millions of voters as the 50th anniversary of Roe v. Wade.
“With a divided Congress for the next two years, and a 2024 presidential race that will bring surprises and uncertainty to the nation, here’s what we know: Big battles for reproductive access will be fought in the next two years and beyond,” said Rob Bonta (D ), attorney general of California.
The anti-abortion movement is also developing a new strategy from the state, as its leaders agree to the fall of Roe.
“After all these years, that moment has truly come true. And while we were preparing, nothing really prepares you for the reality in this area,” said Marjorie Dansfeller, president of Susan B. Anthony Pro-Life America, one of the country’s anti-abortion groups.
“This is week one of the beginnings of a new life for our team.”
The end of Roe also brought significant changes to the annual March for Life event on the National Mall.
Anti-abortion groups have held the event every year since 1974 – the year after the Roe decision.
Although the initial goal of the march has been accomplished, supporters turned out Friday for the latest march to show support for Roe’s downfall and set new goals.
The FTC wants to hold Shkreli in contempt
The Federal Trade Commission (FTC) on Friday asked a federal judge to hold the famous “brother” Martin Shkreli in contempt for failing to pay a $65 million fine and violating a lifetime ban from working in the pharmaceutical industry.
In filings filed in federal court in the Southern District of New York, the FTC and regulators from several states said Shkreli was in “contempt” of court orders by ignoring subpoenas and interrogatories.
Shkreli in July announced the launch of a new company, Druglike. The company released a press release calling it a “Web3 drug discovery program founded by Martin Shkreli” that aims to revolutionize early drug discovery.
The FTC said it could not assess whether the company violated Shkreli’s lifetime ban, because it had not submitted documents or held inquiries with regulators.
“Martin Shkreli’s failure to comply with the court order demonstrates a complete disregard for the law,” said Holly Vedova, director of the FTC’s Bureau of Competition. “The FTC will not hesitate to send all possible legal action to conduct a thorough investigation of potential misconduct.”
Read more here.
CANCER DIAGNOSIS INCREASE SUICIDE BY 26 PERCENT: PEKU
People diagnosed with cancer between 2000 and 2016 had a 26% higher risk of suicide compared to the general population, a new study shows.
Both insurance and ethnicity contributed to the increased risk, the authors wrote. People who had cognitive impairment at the time of diagnosis were more likely to commit suicide within two years of learning they had the disorder. Patients who had cancer that tended to damage longevity were at a higher risk after the first two years.
However, the highest risk was seen within the first six months after a patient was diagnosed with cancer, where the risk was seven times greater than that of the general population.
These findings emphasize the importance of early symptom management and psychosocial interventions to prevent suicide in cancer patients, the researchers said.
“This requires the efforts of governments and local governments, as well as health care providers, to ensure that all health insurance, psycho-oncological, psychosocial, and palliative care, the implementation of appropriate medical guidelines for assessing the risk of suicide, and the inclusion of suicide prevention. Care plans for survivors ,” lead author Xuesong Han said in a release. Han is the chief scientific officer of health research at the American Cancer Society.
Read more here.
WHAT WE KNOW ABOUT HOW COVID VACCINE CAN WORK
Since the beginning of the pandemic, women have reported experiencing changes in their periods after contracting COVID-19 or receiving vaccinations.
Their journey was long, some say. Their blood was too much. Research has supported these reports, showing the COVID-19 vaccine has a temporary but significant effect on women’s menstrual cycles and symptoms.
Research shows that changes in menstrual cycle length can be caused by the immune system’s effects on sex hormones. Inflammatory responses to the COVID-19 vaccine can also affect the ovaries and uterus.
Here’s what we know:
- A study of about 4,000 women in the US found that the length of the menstrual period was increased by an average of 0.7 days after the first dose and 0.9 days after the second dose. Although the visits were longer, however, the researchers did not find a change in the number of days of a woman’s period.
- A recent study suggests that women may experience more menstrual symptoms after receiving the vaccine.
Read more here.
WHAT WE ARE READING
- With Roe dead, a very different March for Life returns to Washington (Washington Post)
- FDA rejects Lilly’s bid for accelerated approval of its Alzheimer’s drug (Stat)
- New technology offers hope to one million people with epilepsy (NPR)
- Attracting workforce professionals is just the first step in solving Montana’s health care workforce crisis (Kaiser Health News)
- NYU Langone Stops Trial of Type 1 Diabetes Vaccine in Teens (The New York Times)
- New Georgia House Speaker: No Medicaid expansion for all poor yet (Atlanta Journal Constitution)
That’s it for today, thanks for reading. Check out The Hill’s Health Care website for the latest information and news. See you next week.